

### **Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

### **Listing of Claims:**

1 - 37. (Cancelled)

38. (New) An *in vitro* method of functionally determining at physiological conditions deficiencies in the lectin pathway of the complement system, employing a sample of mammalian blood, serum, plasma, or another body fluid obtained from a mammal, the method comprising the steps of

- (a) adding an C1 complex inhibitor selected from the group consisting of proteins, peptides or immunoglobulins against C1q, C1r or C1s;
- (b) diluting the sample to inhibit the activation of the alternative pathway;
- (c) adding a MBL (mannan-binding lectin) or ficolin binding carbohydrate activating the lectin pathway in the sample;
- (d) adding an first antibody against the autologous C5b-9 complex and
- (e) determining the activation of the lectin pathway at the physiological condition by measuring the autologous C5b-9 complex.

39. (New) The method according to claim 38, wherein the inhibitor in step (a) is selected from the group consisting of C1 inhibitor, CRT, C1Qr, E.coli C1g binding protein, gC1qR, ghB3, decorin, chondroitin sulphate proteoglycan, surfactant protein A and HNP-1.

40. (New) The method according to claim 38, wherein the inhibitor in step (a) is selected from the group consisting of TDGDKAFVDFLSDEIKKEE, KDIRCKDD, AEAKAKA, VQVHNAKTKPR, WY, CEGPFGPRHDLTFCW and LEQGENVFLQATLL.

41. (New) The method according to claim 38, wherein the inhibitor in step (a) is selected from the group consisting of polyclonal and monoclonal antibodies.

42. (New) The method according to claim 38, wherein the carbohydrate in step (c) is selected from the group consisting of mannose, fucose, mannan such as glucomannan and galactomannan, synthetic carbohydrate and microbial polysaccharide.
43. (New) The method according to claim 38, wherein the first antibody in step (d) is a polyclonal or a monoclonal antibody.
44. (New) The method according to claim 43, wherein the step in (d) comprises adding a second antibody against the first antibody, wherein said second antibody is a labeled antibody.
45. (New) The method according to claim 43, wherein the first antibody is a labeled antibody.
46. (New) A kit for functionally determining in a body fluid from a mammal deficiencies in the lectin pathway of the complement system, which kit comprises (a) an inert carrier and a MBL or ficolin binding carbohydrate (b) a diluent comprising a C1 complex inhibitor selected from the group consisting of peptides, proteases or immunoglobulins against C1q, C1r or C1s and (c) a first antibody against the autologous C5b-9 complex.
47. (New) The kit according to claim 46, wherein the carbohydrate in (a) is selected from the group consisting of mannose, fucose, mannan such as glucomannan and galactomannan, synthetic carbohydrate and microbial polysaccharide.
48. (New) The kit according to claim 46, wherein the inhibitor in (b) is selected from the group consisting of C1 inhibitor, CRT, C1Qr, E.coli C1g binding protein, gC1qR, ghB3, decorin, chondroitin sulphate proteoglycan, surfactant protein A and HNP-1.
49. (New) The kit according to claim 46, wherein the inhibitor in (b) is selected from the group consisting of the peptides, TDGDKAFVDLSDEIKKEE, KDIRCKDD,

AEAKAKA, VQVHNAKTKPR,WY,CEGPFGRHDLTFCW and  
LEQGENVFLQATLL.

50. (New) The kit according to claim 46, wherein the inhibitor in (b) is selected from the group consisting of polyclonal and monoclonal antibodies.

51. (New) The kit according to claim 46, wherein the first antibody in (c) is a polyclonal or monoclonal antibody.

52. (New) The kit according to claim 47, wherein the carbohydrate in (a) is coated on the inert carrier.

53. (New) The kit according to claim 51, wherein the first antibody in (c) is a labeled antibody.

54. (New) The kit according to claim 51, wherein the kit further comprises a labeled second antibody (d) against the antibody in (c).

55. (New) The kit according to claim 53, wherein the kit further comprises an enzyme substrate (e).

56. (New) The kit according to claims 46, wherein the kit further comprises a washing solution (f).

57. (New) The kit according to claim 46, wherein the kit further comprises a normal body liquid from a mammal (g).

58. (New) The kit according to claim 57, wherein the normal body liquid (g) is a human serum.

59. (New) The kit according to claim 46, wherein the kit further comprises an inactivated normal body liquid from a mammal (h).

60. (New) The kit according to claim 59, wherein the inactivated normal body liquid (h) is heat inactivated human serum.